Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were resolved as presented in the notice issued on 19 April 2024 and the recommendations from the Election committee.

The minutes from the Annual General Meeting are attached.

For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads.  Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung").

Other leads are focused on using the Company's bioactive peptides as a Medical Food   for the protection of the Gastro- Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotizing enterocolitis). The Company is founded on the core values of sustainability, optimal   utilization of natural resources and full traceability.  Through innovative and patent protected hydrolysis technology, HBC can preserve the quality of the lipids, proteins and calcium from fresh salmon off-cuts.
HBC's headquarters are in Ålesund, Norway with offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.

HBC is listed on Oslo Børs with ticker "HBC". More information about HBC at hofsethbiocare.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act